Key result
Treatment with intra-arterial tolazoline and heparin for nonocclusive mesenteric ischemia after cardiopulmonary bypass resulted in an overall mortality rate of 30% (7 of 23 patients).
Why the study?
Does intra-arterial infusion of tolazoline and heparin improve survival in patients with nonocclusive mesenteric ischemia after cardiopulmonary bypass?
Observational (n=3,600)
Does intra-arterial infusion of tolazoline and heparin improve survival in patients with nonocclusive mesenteric ischemia after cardiopulmonary bypass?
Intra-arterial infusion of tolazoline and heparin appears to be a viable treatment strategy for nonocclusive mesenteric ischemia following cardiopulmonary bypass, yielding a 30% mortality rate in this high-risk cohort.
This retrospective study evaluates our experience with clinically diagnosed nonocclusive mesenteric ischemia after cardiopulmonary bypass. Twenty-three of 3,600 consecutive patients suffered from splanchnic malperfusion. Symptoms developed between day 2 and 6 postoperatively in 18 of 23 patients. Four of 23 patients had no abdominal symptoms. Laboratory evaluation revealed significantly higher serum lactate and creatine phosphokinase levels in the 18 symptomatic patients compared with those of a control group. Arteriography was performed in 20 cases and revealed nonocclusive splanchnic hypoperfusion. Risk factors for development of mesenteric ischemia include arrhythmias and low cardiac output. Patients with angiographically proven nonocclusive mesenteric ischemia were treated with intra-arterial bolus injection and subsequent intra-arterial infusion of tolazoline combined with heparin sodium. The overall mortality rate was 30% (7 of 23). Infusion therapy with tolazoline and heparin seems to be a successful treatment modality for clinically diagnosed mesenteric ischemia.
No takes yet. Share an insight, caveat, or question.
Huwer et al. (2004) conducted an observational in Nonocclusive mesenteric ischemia after cardiopulmonary bypass (n=3,600). Intra-arterial tolazoline and heparin sodium was evaluated on Overall mortality. Treatment with intra-arterial tolazoline and heparin for nonocclusive mesenteric ischemia after cardiopulmonary bypass resulted in an overall mortality rate of 30% (7 of 23 patients).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: